Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smolen

Showing results (1131-1140 of 1,467) with videos related to

Pageof 147
Sort By:
The Journal of Experimental Medicine|March 23, 2005
CD44 is a determinant of inflammatory bone lossSilvia Hayer, Günter Steiner, Birgit Görtz, et al.
Computers in Nursing|March 31, 2000
Computerized test development software. A comparative review updatedJ M Kirkpatrick, D M Billings, K Hodson-Carlton, et al.
The Journal of Allergy and Clinical Immunology|December 3, 2013
Pattern recognition receptor-mediated cytokine response in infants across 4 continentsKinga K Smolen, Candice E Ruck, Edgardo S Fortuno, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 13, 2005
Aberrant expression of the autoantigen heterogeneous nuclear ribonucleoprotein-A2 (RA33) and spontaneous formation of rheumatoid arthritis-associated anti-RA33 autoantibodies in TNF-alpha transgenic miceSilvia Hayer, Makiyeh Tohidast-Akrad, Silva Haralambous, et al.
Annals of the Rheumatic Diseases|October 28, 2006
Consensus statement on the use of rituximab in patients with rheumatoid arthritisJ S Smolen, E C Keystone, P Emery, et al.
Experimental & Molecular Medicine|July 10, 2019
IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes : JAKinibs suppress the interferon response in RA-FLSsMichael Bonelli, Karolina Dalwigk, Alexander Platzer, et al.
Lancet (London, England)|January 22, 2013
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trialJosef S Smolen, Peter Nash, Patrick Durez, et al.
Annals of the Rheumatic Diseases|November 2, 2016
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)Josef S Smolen, Joel M Kremer, Carol L Gaich, et al.
Arthritis and Rheumatism|September 29, 1998
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisR N Maini, F C Breedveld, J R Kalden, et al.
Annals of the Rheumatic Diseases|September 30, 2019
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trialPhilip J Mease, Josef S Smolen, Frank Behrens, et al.
Pageof 147

Showing results (1131-1140 of 1,467) with videos related to

Sort By:
Pageof 147
The Journal of Experimental Medicine|March 23, 2005
CD44 is a determinant of inflammatory bone lossSilvia Hayer, Günter Steiner, Birgit Görtz, et al.
Computers in Nursing|March 31, 2000
Computerized test development software. A comparative review updatedJ M Kirkpatrick, D M Billings, K Hodson-Carlton, et al.
The Journal of Allergy and Clinical Immunology|December 3, 2013
Pattern recognition receptor-mediated cytokine response in infants across 4 continentsKinga K Smolen, Candice E Ruck, Edgardo S Fortuno, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 13, 2005
Aberrant expression of the autoantigen heterogeneous nuclear ribonucleoprotein-A2 (RA33) and spontaneous formation of rheumatoid arthritis-associated anti-RA33 autoantibodies in TNF-alpha transgenic miceSilvia Hayer, Makiyeh Tohidast-Akrad, Silva Haralambous, et al.
Annals of the Rheumatic Diseases|October 28, 2006
Consensus statement on the use of rituximab in patients with rheumatoid arthritisJ S Smolen, E C Keystone, P Emery, et al.
Experimental & Molecular Medicine|July 10, 2019
IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes : JAKinibs suppress the interferon response in RA-FLSsMichael Bonelli, Karolina Dalwigk, Alexander Platzer, et al.
Lancet (London, England)|January 22, 2013
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trialJosef S Smolen, Peter Nash, Patrick Durez, et al.
Annals of the Rheumatic Diseases|November 2, 2016
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)Josef S Smolen, Joel M Kremer, Carol L Gaich, et al.
Arthritis and Rheumatism|September 29, 1998
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisR N Maini, F C Breedveld, J R Kalden, et al.
Annals of the Rheumatic Diseases|September 30, 2019
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trialPhilip J Mease, Josef S Smolen, Frank Behrens, et al.
Pageof 147